Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Recommendation of “Hold” by Analysts

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has been assigned a consensus rating of “Hold” from the five research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $39.3333.

Several analysts have commented on ETON shares. HC Wainwright raised their price objective on shares of Eton Pharmaceuticals from $37.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, March 20th. B. Riley Financial raised their price objective on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Zacks Research lowered shares of Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, April 17th. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Finally, Craig Hallum raised their price objective on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, March 20th.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several large investors have recently made changes to their positions in ETON. Millennium Management LLC lifted its holdings in shares of Eton Pharmaceuticals by 156.3% during the first quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after purchasing an additional 217,042 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Eton Pharmaceuticals by 34.9% during the first quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company’s stock valued at $2,274,000 after purchasing an additional 45,341 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Eton Pharmaceuticals by 49.1% during the first quarter. Jane Street Group LLC now owns 95,919 shares of the company’s stock valued at $1,245,000 after purchasing an additional 31,596 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Eton Pharmaceuticals by 114.5% during the second quarter. JPMorgan Chase & Co. now owns 242,580 shares of the company’s stock valued at $3,457,000 after purchasing an additional 129,467 shares during the last quarter. Finally, Legal & General Group Plc purchased a new position in shares of Eton Pharmaceuticals during the second quarter valued at approximately $41,000. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Stock Performance

Shares of ETON opened at $28.90 on Monday. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.57 and a quick ratio of 1.17. Eton Pharmaceuticals has a one year low of $13.09 and a one year high of $29.80. The company has a 50-day simple moving average of $21.94 and a two-hundred day simple moving average of $18.48. The firm has a market capitalization of $790.70 million, a PE ratio of -160.55 and a beta of 0.82.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings data on Thursday, March 19th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.07). Eton Pharmaceuticals had a negative return on equity of 2.60% and a negative net margin of 5.75%.The company had revenue of $21.28 million during the quarter, compared to analysts’ expectations of $20.58 million. On average, analysts anticipate that Eton Pharmaceuticals will post 0.82 EPS for the current fiscal year.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.